| | Author | Year | Nation | No. (M/F) | Age | Stage | Grade | Cut-off value | Outcome | Data extraction | Other costudied genes | Antibody source (dilution) | Detection method of p16 |
| |
Orlow et al. [4] | 1999 | Canada | 120 | NR | Ta–T1 | G1–G3 | Score = 3 | RFS/CP | Reported | P14 | Vector (1 : 500) | Immunohistochemistry | |
Bartoletti et al. [8] | 2007 | Italy | 56 (50/6) | 70.1 (45–89) | Ta–T1 | G1-G2 | 10% | RFS | Reported | 9p21 | Bio-Optica (1 : 25) | Immunohistochemistry | |
Chakravarti et al. [9] | 2005 |
USA | 50 (36/14) | NR | T2–T4 | High | 20% | OS/FFS/DSS | Reported | Erb-1, Erb-2, P53, PRB | Zymed (NR) | Immunohistochemistry | |
Hitchings et al. [10] | 2004 | UK | 78 | 66 (24–90) | Ta–T1 | G1–G3 | 10% | PFS/RFS/CP | Reported | P53, PRB | Novocastra (1 : 50) | Immunohistochemistry | |
Krüger et al. [5] | 2005 | Germany | 73 (60/13) | 68 (NR) | T1 | G2-G3 | 10% | RFS/PFS | Reported | NR | Biocarta (1 : 50) | Immunohistochemistry | |
Lee et al. [11] | 2010 | Korea | 47 (4/43) | NR | Ta–T4 | Low and high | Score = 5 | OS/CP | Reported | P53, PRB | DAKO (1 : 200) | Immunohistochemistry | |
Mhawech et al. [12] | 2004 | Switzerland | 49 (44/5) | 70.3 (52–90) | T1 | Low and high | Score = 3 | PFS/CP | Reported | P21 | DAKO (1 : 20) | Immunohistochemistry | |
Yang et al. [13] | 2002 | China | 67 | NR | T1-T2 | G1–G3 | 5% | RFS/CP | Binary variable | Cyclin D1, CCNE, p27, p21, p53 | Santa Cruz (NR) | Immunohistochemistry | |
Brunner et al. [14] | 2008 | Switzerland | 99 | NR | Ta–T4 | Low and high | 1.5% or 23% | OS/RFS | Survival curve | MTS | NeoMarkers (1 : 50) | Immunohistochemistry | |
Friedrich et al. [15] | 2001 | Germany | 40 | NR | Ta–T1 | G1–G3 | 5% | RFS/CP | Survival curve | LOH | Pharmingen (1 : 100) | Immunohistochemistry | |
Korkolopoulou et al. [16] | 2001 | Greece | 23 | 72 (35–92) | T3-T4 | Low and high | 5% | OS/CP | Survival curve | P53 | Santa Cruz (1 : 100) | Immunohistochemistry | |
Niehans et al. [17] | 1999 | USA | 78 | 64.7 (48–82) | T1–T4 | G2–G4 | Score = 4 | DSS/CP | Survival curve | P53, PRB, cyclin D1 | Pharmingen (1 : 400) | Immunohistochemistry | |
Røtterud et al. [18] | 2002 | Norway | 59 | 64 (42–75) | T2–T4 | G2-G3 | Score = 3 | CSS/CP | Survival curve | p21, p27 | NeoMarkers (1 : 100) | Immunohistochemistry | |
Vallmanya Llena et al. [19] | 2006 | Spain | 97 | NR | Ta–T1 | Low and high | 15% | RFS/PFS/OS/CP | Survival curve | p53, p21 | DakoCytomation (NR) | Immunohistochemistry | |
Sun et al. [20] | 2000 | China | 60 | NR | Tis–T4 | G1–G3 | Score = 4 | OS | Survival curve | PRb | Santa Cruz (1 : 100) | Immunohistochemistry | |
Santos et al. [21] | 2003 | Portugal | 56 (40/16) | 70 (43–83) | Ta–T1 | G1-G2 | 20% | RFS/CP | Binary variable | p27, pRb, p53, Ki-67 | Pharmingen (1 : 500) | Immunohistochemistry | |
Yin et al. [22] | 2008 | USA | 18 | NR | T1–T4 | Low and high | Score = 4 | CP | Binary variable | 9p21 | Pharmingen (1 : 250) | Immunohistochemistry | |
Primdahl et al. [23] | 2002 | Denmark | 69 (55/14) | 71 (42–83) | Ta–T4 | G1–G4 | Score = 4 | CP | Binary variable | Rb, p27, p21, L-myc | NeoMarkers (1 : 50) | Immunohistochemistry | |
Jin et al. [24] | 2006 | USA | 39 (25/14) | 65 (42–84) | T2–T4 | G1–G4 | 10% | CP | Binary variable | P53, pRB | NR (1 : 50) | Immunohistochemistry | |
Tzai et al. [25] | 2004 | China (Taiwan) | 65 (44/21) | 61.5 (41–84) | T2–T4 | G2-G3 | Score = 4 | CP | Binary variable | P53, pRB | Santa Cruz (1 : 20) | Immunohistochemistry | |
Jin et al. [26] | 2004 | China | 62 (32/30) | 61 (18–80) | Tis–T4 | G1–G3 | OC | CP | Binary variable | Cyclin D1, PCNA | NR | Immunohistochemistry | |
Fu and Li [27] | 2011 | China | 50 (39/11) | 59.3 (32–81) | Tis–T4 | G1–G3 | 10% | CP | Binary variable | E-cadherin | NR | Immunohistochemistry | |
Shi et al. [28] | 2001 | China | 62 (52/10) | 58.5 (22–87) | Tis–T4 | G1–G3 | Score = 3 | RFS/CP | Binary variable | PCNA | Zymed (1 : 50) | Immunohistochemistry | | Wang [29] | 2001 | China | 49 (39/10) | 61 (22–89) | NR | G1–G3 | 10% | RFS/CP | Binary variable | NR | NR | Immunohistochemistry | |
Miao [30] | 1999 | China | 50 | NR | Tis–T4 | G1–G3 | OC | RFS/OS/CP | Binary variable | Cyclin D1 | Santa Cruz (1 : 100) | Immunohistochemistry | |
Shi et al. [31] | 2003 | China | 82 (65/17) | 58.7 (24–72) | Tis–T4 | G1–G3 | OC | RFS/CP | Binary variable | Cyclin D1 | NR | Immunohistochemistry | | Yang [32] | 2005 | China | 69 (62/7) | 61 (42–75) | Tis–T4 | G1–G3 | 5% | RFS/CP | Binary variable | P27/nm23 | NR | Immunohistochemistry | |
Wang et al. [33] | 2013 | China | 45 (30/15) | 65 (38–80) | NR | H/L | 5% | RFS/CP | Binary variable | PTEN/P53 | NR | Immunohistochemistry | |
Leng et al. [34] | 2000 | China | 51 (43/8) | 53.4 (28–72) | Tis–T3 | G1–G3 | OC | RFS/OS/CP | Binary variable | bcl-2 | Santa Cruz (1 : 50) | Immunohistochemistry | |
Bai and Xiong [35] | 2014 | China | 65 (50/15) |
(57.7 ± 8.2) | Tis–T4 | H/L | 5% | CP | Binary variable | mfn2 | Zymed (NR) | Immunohistochemistry | |
Wang et al. [36] | 2000 | China | 75 (62/13) | 58.5 (24–81) | Tis–T4 | G1–G3 | OC | CP | Binary variable | c-erbB-2, p53 | Maxim (1 : 50) | Immunohistochemistry | |
Wang et al. [37] | 2006 | China | 55 (35/20) | 63 (24–75) | Tis–T4 | G1–G3 | 10% | CP | Binary variable | hTERT, cyclin D1, RB | NR | Immunohistochemistry | |
Lu et al. [38] | 2008 | China | 40 (30/10) | 54.2 (37–79) | Tis–T4 | G1–G3 | 10% | CP | Binary variable | p53, PCNA | NR (1 : 50) | Immunohistochemistry | |
Xie et al. [39] | 2003 | China | 72 (56/16) | NR (29–78) | Tis–T4 | G1–G3 | 5% | RFS/CP | Binary variable | Rb, cyclin D1 | Zymed (1 : 50) | Immunohistochemistry | |
Qiu et al. [40] | 2006 | China | 53 (46/7) | 61 (25–83) | Tis–T4 | G1–G3 | 15% | CP | Binary variable | NR | NR | Immunohistochemistry | |
Rebouissou et al. [41] | 2012 | France | 89 | NR | Ta–T1 | G1–G3 | Score = 3 | RFS/PFS | Survival curve | FGFR3 | NR | FISH | |
Abat et al. [42] | 2014 | Turkey | 34 (30/4) | NR | T1–T4 | Low and high | OC | PFS | Reported | p53 | NR | FISH |
|
|
